Lonza has unveiled a manufacturing expansion as part of an evolving production pact that’s set to create nearly 200 new jobs at “one of the largest bioconjugation facilities globally.” Lonza has extended a long-term collaboration with an unnamed “major global biopharmaceutical partner” to crank up commercial supplies of antibody-drug conjugates (ADCs) at its site in Visp, Switzerland. The deal is set to boost Lonza’s current bioconjugation capacity fourfold, thanks to the addition of two new bioconjugation suites in Visp, the CDMO said in a release. Source: Fierce Pharma 5/10/2023